European Medicines Agency (EMEA)
CHMP revised EPARs started on:
- Axura, Memantine, Revision:16, Authorised
- Ebixa, Memantine, Revision: 19, Authorised
- Exelon, Rivastigmine, Revision: 24, Authorised
- Invega, Paliperidone, Revision: 7, Authorised
- Lyrica, Pregablin, Revision: 17, Authorised
- Nimvastid, Rivastigmine, Revision: 3, Authorised
- Rivastigmine 1 A Pharma, Rivastigmine, Revision: 2, Authorised
- Rivastigmine Hexal, Rivastigmine, Revision: 2, Authorised
- Rivastigmine Sandoz, Rivastigmine, Revision: 2, Authorised
- Rivastigmine Teva, Rivastigmine, Revision: 4, Authorised
- Sycrest, Asenapine, Revision: 3, Authorised
- Xeplion, Paliperidone, Revision: 2, Authorised
- Zypadhera, Olanzapine, Revision: 4, Authorised
- Zyprexa Velotab, Olanzapine, Revision: 19, Authorised
- Zyprexa, Olanzapine, Revision: 26, Authorised
Pending EC decision:
- Ariclaim, Duloxetine
- Cymbalta, Duloxetine
- Xeristar, Duloxetine
Opinion/Decision on:
- Paediatric Investigation Plan (PIP): -, (1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,2,2-dioxide, monohydrate (LY2140023)
- Paediatric Investigation Plan (PIP): -, 1-[2-(2,4-Dimethyl-phenylsulfanyl)phenyl]piperazine (Lu AA21004)
News:
- European Medicines Agency formalises interaction with healthcare professionals
|